Planned cryopreservation of all embryos also allows clinicians to administer a GnRH agonist trigger, further minimising the risk of OHSS and allowing clinics to achieve very low rates of moderate-to-severe OHSS in these high risk patients (3, 99). This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.